evolocumab
amgen
['yellow iii']
stable cad plaque morphology improved by pcsk9 inhibitors: yellow iii by #acc23
Birthplace of 9 most measurable modifiable risk factors for #heartdisease & #stroke @McMasterU @hamhealthsci Newsletter: https://t.co/mpqGNzERCA | https://t.co/J8M2DKtXyS